Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

269 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined bedtime insulin--daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate--a randomised trial.
Stehouwer MH, DeVries JH, Lumeij JA, Adèr HJ, Engbers AM, Iperen Av Av, Snoek FJ, Heine RJ. Stehouwer MH, et al. Among authors: snoek fj. Diabetes Metab Res Rev. 2003 Mar-Apr;19(2):148-52. doi: 10.1002/dmrr.356. Diabetes Metab Res Rev. 2003. PMID: 12673783 Clinical Trial.
Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes.
Swinnen SG, Snoek FJ, Dain MP, DeVries JH, Hoekstra JB, Holleman F. Swinnen SG, et al. Among authors: snoek fj. Diabetes Technol Ther. 2009 Nov;11(11):739-43. doi: 10.1089/dia.2009.0044. Diabetes Technol Ther. 2009. PMID: 19905891 Clinical Trial.
A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.
Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Pfeiffer AF, Snoek FJ, Devries JH, Hoekstra JB, Holleman F. Swinnen SG, et al. Among authors: snoek fj. Diabetes Care. 2010 Jun;33(6):1176-8. doi: 10.2337/dc09-2294. Epub 2010 Mar 3. Diabetes Care. 2010. PMID: 20200301 Free PMC article. Clinical Trial.
Design and rationale of the IN CONTROL trial: the effects of real-time continuous glucose monitoring on glycemia and quality of life in patients with type 1 diabetes mellitus and impaired awareness of hypoglycemia.
van Beers CA, Kleijer SJ, Serné EH, Geelhoed-Duijvestijn PH, Snoek FJ, Kramer MH, Diamant M. van Beers CA, et al. Among authors: snoek fj. BMC Endocr Disord. 2015 Aug 21;15:42. doi: 10.1186/s12902-015-0040-3. BMC Endocr Disord. 2015. PMID: 26292721 Free PMC article. Clinical Trial.
Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial.
van Beers CA, DeVries JH, Kleijer SJ, Smits MM, Geelhoed-Duijvestijn PH, Kramer MH, Diamant M, Snoek FJ, Serné EH. van Beers CA, et al. Among authors: snoek fj. Lancet Diabetes Endocrinol. 2016 Nov;4(11):893-902. doi: 10.1016/S2213-8587(16)30193-0. Epub 2016 Sep 15. Lancet Diabetes Endocrinol. 2016. PMID: 27641781 Clinical Trial.
269 results